Progressive, and cell type-specific lncRNA dysregulation in the HGPS vasculature is revealed and lncRNAs are highlighted as candidates for exploring new therapeutic strategies.
Abstract
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare premature aging disorder caused by de novo LMNA mutations. Patients develop severe systemic symptoms limiting life quality and ultimately causing death from cardiovascular events. Despite extensive research, treatment options remain limited. Here, we investigated the role of long non-coding RNAs (lncRNAs) in the development of vascular pathology in HGPS. We analyzed an available single-cell RNA sequencing dataset from aortic arch cells of wild-type and LmnaG609G/G609G mice aged 6, 10 and 12 weeks. Several lncRNAs implicated in cardiovascular disease, such as Carmn, Dancr, Gas5, Kcnq1ot1, Meg3, Neat1, Pvt1, or Trp53cor1, were dysregulated in LmnaG609G/G609G vascular smooth muscle cells (VSMCs). This dysregulation was most pronounced in disease-enriched VSMCs, which showed severe dysfunction with disease progression. Furthermore, lncRNA changes were dynamic over time. Transcription factor motif enrichment analysis identified putative regulatory links between dysregulated lncRNAs, and cellular programs associated with VSMC stress responses and phenotypic switching. In contrast, LmnaG609G/G609G fibroblasts displayed a distinct lncRNA expression profile, including H19, Gas5, Kcnq1ot1, and Pvt1, associated with fibrosis and inflammation. Together, our findings reveal progressive, and cell type-specific lncRNA dysregulation in the HGPS vasculature and highlight lncRNAs as candidates for exploring new therapeutic strategies.
This purely computational study identifies candidate dysregulated lncRNAs and predicted lncRNA–miRNA interactions in APS neutrophils, providing a hypothesis-generating framework for future experimental validation.
Yash Bisht, S. Joshi, Kajal Yadav et al.· Discover Informatics· 0 citations
Hutchinson-Gilford progeria syndrome (HGPS) is characterized by progressive vascular injury that remains incompletely controlled by therapies targeting progerin-associated pathology. Here, we investigated the therapeutic activity and molecular mechanisms of melatonin-preconditioned mesenchymal stromal cell-derived smal...
E. Joo, Unyoung Yoon, Jaeyoung Lee et al.· Pharmacological Research· 0 citations
It is demonstrated that TMZ mitigates dystrophic pathology by targeting the ATP6AP2 signaling axis and dampening macrophage-mediated inflammatory responses, highlighting its potential as a novel immunopharmacological therapeutic strategy for DMD.
Lin Zhou, Yu Zhang, Xinxin Tan et al.· International Immunopharmaco...· 0 citations
It is found that global m6A levels are significantly elevated in CoA tissues, with widespread hypermethylation events enriched in focal adhesion and extracellular matrix remodeling pathways, providing novel epigenetic targets for therapeutic intervention.
Wen-Lei Li, Wei-Dan Chen, Minghui Zou et al.· Frontiers in Cardiovascular...· 0 citations
Structural and network analyses provide a hypothesis-generating framework for prioritizing candidate regions and interactions for future transcript-specific methylation mapping and functional validation in APS and suggest broader epitranscriptomic dysregulation.
C. A. Guzmán-Martín, Y. Juárez-Vicuña, R. Bojalil et al.· Biomolecules· 0 citations
Despite enormous advances in clinical genomics, idiopathic scoliosis remains an enigmatic condition with poorly understood genetic and pathophysiological underpinnings impeding molecular diagnosis and the development of targeted treatments. We performed linkage analysis, exome, genome and short- and long-read RNA seque...
Tanja Frey, Elena M. Cabello, Gabriele Siegel et al.· Journal of Clinical Investig...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.